Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARIFI: Zenapax vs Sandimmun Neoral in Renal Transplant Recipients
NCT00138970Phase 4Completed
- Sponsor
- University of Oslo School of Pharmacy
- Start
- Jan 2002
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of daclizumab in kidney transplant rejection, sponsored by University of Oslo School of Pharmacy. Started Jan 2002; status: completed.
02
Drugs
daclizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00138970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138970.